Working… Menu

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PANAMO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04333420
Recruitment Status : Recruiting
First Posted : April 3, 2020
Last Update Posted : August 31, 2021
Information provided by (Responsible Party):
InflaRx GmbH

Brief Summary:

Phase II & Phase III:

This is a pragmatic, adaptive, randomized, multicenter phase II/III study evaluating IFX-1 for the treatment of COVID-19 related severe pneumonia. The study consists of two parts: Phase II, an open-label, randomized, 2-arm phase evaluating best supportive care (BSC) + IFX-1 (Arm A) and BSC alone (Arm B); and Phase III, a double-blind, placebo-controlled, randomized phase comparing standard of care (SOC) + IFX-1 (Arm A) versus SOC + placebo-to-match (Arm B)

Condition or disease Intervention/treatment Phase
Severe COVID-19 Pneumonia Drug: SOC + IFX-1 Drug: SOC + Placebo Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 390 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Phase II: Open label study (30 patients) Phase III: Double- blind; (360 patients)
Primary Purpose: Treatment
Official Title: A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
Actual Study Start Date : March 31, 2020
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Experimental: Arm A: SOC + IFX-1 Drug: SOC + IFX-1

Experimental: Arm B : SOC + Placebo Drug: SOC + Placebo
SOC + Placebo

Primary Outcome Measures :
  1. Mortality [ Time Frame: Day 28 ]
    28-day all-cause mortality

Secondary Outcome Measures :
  1. Treatment Emergent Adverse Events [ Time Frame: Day1 to Day 60 ]
    Frequency, severity, and relatedness to study drug of serious and non-serious TEAEs

  2. Safety Parameters [ Time Frame: Day 15, Day 28 ]
    Proportion of patients with an improvement in the 8-point ordinal scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age or older
  • Clinically evident or otherwise confirmed severe pneumonia
  • SARS-CoV-2 infection confirmation (tested positive in last 14 days before randomization with locally available test system)

Exclusion Criteria:

  • Known history of progressed COPD as evidenced by use of daily maintenance treatment with long-acting bronchodilators or inhaled/oral corticosteroids for > 2 months
  • Patient moribund or expected to die in next 24h according to the judgment of the investigator
  • Known severe congestive heart failure (New York Heart Association [NYHA] Class III- IV
  • Received organ or bone marrow transplantation in past 3 months
  • Known cardio-pulmonary mechanical resuscitation in past 14 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04333420

Layout table for location contacts
Contact: Korinna Pilz, MD +49 89 4141 89 78 ext 0

Show Show 39 study locations
Sponsors and Collaborators
InflaRx GmbH
Layout table for investigator information
Principal Investigator: A Vlaar, MD University Amsterdam
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: InflaRx GmbH Identifier: NCT04333420    
Other Study ID Numbers: IFX-1-P2.9
First Posted: April 3, 2020    Key Record Dates
Last Update Posted: August 31, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by InflaRx GmbH:
COVID-19 related severe pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections